AgingResearch.NewsJoin free

Senolytics + ANTI-PD-1 therapy

Intervention

1 paper2 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

  • 1 lab in 1 country
  • Funders: Basic and Applied Basic Research Foundation of Guangdong Province and 4 more
  • Human trial1

Outcomes

2

Immunosenescence

downin humans1

1 study

  1. Senolytics + ANTI-PD-1 therapy decreases immunosenescence in humans.

    “The clinical results demonstrate that this therapeutic strategy is associated with a favorable safety profile and therapeutic efficacy, significantly mitigating adverse effects and alleviating immunosenescence.”

    Human trialPhase II COIS-01 trial

    Reversing Immunosenescence with Senolytics to Enhance Tumor Immunotherapy

    medRxiv15 Oct 2024Preprint

Adverse effects

downin humans1

1 study

  1. Senolytics + ANTI-PD-1 therapy decreases adverse effects in humans.

    “The clinical results demonstrate that this therapeutic strategy is associated with a favorable safety profile and therapeutic efficacy, significantly mitigating adverse effects and alleviating immunosenescence.”

    Human trialPhase II COIS-01 trial

    Reversing Immunosenescence with Senolytics to Enhance Tumor Immunotherapy

    medRxiv15 Oct 2024Preprint

Latest

Related